Evaluation of Biological Effects of Nanosystems of Directed Transport in Experiments in Vivo and Their Application Possibilities in Anti-Tumor Therapy


The aim of the investigations was to evaluate benefits of the directed transport system - a nanocomposite, based on cisplatin and magnetite combined with local action of constant magnetic field on the tumor, in experiments in vivo in animals with transplantable Guerin carcinoma. Animals were divided into 5 groups according to the type of agent. We showed that nanocomposite in combination with static magnetic field exercises more prominent anti-tumor activity than cisplatin alone. It should be noted that regardless of the therapeutic agent, in Guerin carcinoma we observed

Share and Cite:

Chekhun, V. , Naleskina, L. , Polishchuk, L. , Todor, I. , Demash, D. and Lukianova, N. (2013) Evaluation of Biological Effects of Nanosystems of Directed Transport in Experiments in Vivo and Their Application Possibilities in Anti-Tumor Therapy. Advances in Nanoparticles, 2, 145-153. doi: 10.4236/anp.2013.22023.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] S. K. Sahoo, S. Parveen and J. J. Panda, “The Present and Future of Nanotechnology in Human Health Care,” Nanomedicine, Vol. 3, No. 1, 2007, pp. 20-31. doi:10.1016/j.nano.2006.11.008
[2] X. Dong and R. J. Mumper, “Nanomedicinal Strategies to Treat Multidrug-Resistant Tumors: Current Progress,” Nanomedicine, Vol. 5, No. 4, 2010, pp. 597-615.
[3] X. Chi, D. Huang D, Z. Zhao, Z. Zhou, Z. Yin and J. Gao, “Nanoprobes for in Vitro Diagnostics of Cancer and Infectious Diseases,” Nanomaterials, Vol. 33, No. 1, 2012, pp.189-206.
[4] J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, “Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008”, International Journal of Cancer, Vol. 127, No. 12, 2010, pp. 2893-2917. doi:10.1002/ijc.25516
[5] M. Chadambram, R. Manavalan and K. Kathiresan, “Nanotherapeutics to Overcome Conventional Cancer Chemotherapy Limitations,” Journal of Pharmacy and Pharmaceutical Sciences, Vol. 14, No.1, 2011, pp. 67-77.
[6] O. P. Singh and R. M. Nehru, “Nanotechnology and Cancer Treatment,” Asian Journal of Experimental Sciences, Vol. 22, No. 2, 2008, p. 6.
[7] R. Sinha, G. J. Kim, S. Nie and D. M. Shin, “Nanotechnology in Cancer Therapeutics: Bioconjugated Nanoparticles for Drug Delivery,” Molecular Cancer Therapeutics, Vol. 5, No. 8, 2006, pp. 1909-1917. doi:10.1158/1535-7163.MCT-06-0141
[8] B. Haley and E. Frenkel, “Nanoparticles for Drug Delivery in Cancer Treatment,” Urologic Oncology, Vol. 26, No. 1, 2008, pp. 57-64. doi:10.1016/j.urolonc.2007.03.015
[9] V. F. Chekhun, “Role of Innovative Technologies in Solving of Oncological Problems,” Visnyk NAS Ukraine, No. 9, 2008, pp. 38-42.
[10] A. P. Naga and A. Siddiqui, “Nanomedical Platform for Drug Delivery,” Journal of Nanomedicine Nanotechnology, Vol. 2, 2011, p. 122.
[11] E. Gullotti and Y. Yeo, “Extracellularly Activated Nanocarriers: A New Paradigm of Tumor Targeted Drug Delivery,” Molecular Pharmaceutics, Vol. 6, No. 4, 2009, pp. 1041-1051. doi:10.1021/mp900090
[12] H. S. Choi and J. V. Frangioni, “Nanoparticles for Biomedical Imaging: Fundamentals of Clinical Translation,” Molecular Imaging, Vol. 9, No. 6, 2010, pp. 291-310.
[13] B. Szalay, E. Tatrai, G. Nyiro, V. Tunde and G. Dura, “Potential Toxic Effects of Iron Oxide Nanoparticles in in Vivo and in Vitro Experiments,” Journal of Applied Toxicology, Vol. 32, No. 6, 2012, pp. 446-453. doi:10.1002/jat.1779
[14] UA Patent 99211, P. P. Horbyk, “Nanocapsule with Nanorobot Functions,” 2012.
[15] N. Y. Lukianova, N. V. Rusetskaya, L. A. Naleskina and V. F. Chekhun, “Some Mechanisms of Nanocomposit Action on Sensitive and Resistant MCF-7 Cells,” Materials of 7th CIS Oncologists’ and Radiologisits’ Meeting, Kazakhstan, 2012, p. 499.
[16] M. Kates, “Techniques of Lipidology. Isolation, Analysis and Identification of Lipids,” 1975.
[17] V. E. Vaskovsky and T. A. Terekhova, “HPTLC of Phospholipid Mixtures Containing Phosphatidylglycerol,” Journal of High Resolution Chromatography & Chromatography Communications, Vol. 2, No. 2, 1979, pp. 671 672. doi:10.1002/jhrc.1240021107
[18] N. Todor, N. Yu. Lukianova and V. F. Chekhun, “The Lipid Content of Cisplatin and Doxorubicin-Resistant MCF-7 Human Breast Cancer Cells,” Experimental Oncology, Vol. 34, No. 2, 2012, pp. 97-100.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.